As part of this review process, Oramed will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. Oramed has not set a timetable for completion of this review process. There can be no assurance that this process will result in any such transaction and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.
“Over the coming month, our clinical team will continue its deep dive into the unblinded Phase 3 data to assess the optimal way to move forward with our oral insulin assets as well as our platform technology,” stated Chief Executive Officer,
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our future strategy, potential strategic alternatives, plans and prospects, providing further clinical and business updates based on additional analyses, and our discontinuation of clinical trial activities for ORMD-0801. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the Company’s process to evaluate strategic options; the terms, timing, structure, benefits and costs of any strategic transaction and whether any transaction will be consummated at all; the impact of any strategic transaction on the Company; the outcomes of any litigation, regulatory proceedings, inquiries or investigations to which the Company may be subject; the ability to obtain financing or third-party approvals as needed; our ability to achieve the intended benefits of our strategic initiatives; the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; that products may harm recipients; and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, each of which is on file with the
View original content:https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-issues-shareholder-update-301742999.html